This means there's a small amount of cancer left after treatment, like surgery or chemotherapy. It's not a new cancer, but a leftover piece of the original one. Doctors check for this to make sure the cancer hasn't come back.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Residual cancer, also called residual disease or residual tumor, means cancer cells that are still present after treatment intended to remove or destroy the cancer. It is not a separate type of cancer. It describes where someone stands partway through or after treatment of a specific cancer, such as breast, ovarian or colon cancer, or a leukemia. The amount left behind can range from a visible tumor that could not be fully removed, to cells seen only under a microscope at the edge of removed tissue, to a tiny number of cells detectable only with highly sensitive laboratory tests. That last situation is called minimal or measurable residual disease (MRD). Residual disease matters because remaining cells can grow back, so finding it often shapes the next step in treatment and how closely someone is followed.
Residual cancer happens when treatment does not reach every cancer cell. A tumor may have grown into or around an organ, blood vessel or nerve that cannot be safely removed. Cancer can also extend in small strands or patches that the surgeon cannot see or feel. Some cancers respond only partly to chemotherapy, radiation or other medicines. Sometimes leaving some tumor is a deliberate choice. Surgeons may remove most, but not all, of a tumor (debulking) when taking all of it would damage an organ, because shrinking the tumor can help other treatments work better. The chance of residual disease depends mostly on the cancer type, its size and location, how far it has spread and how it responds to treatment. It does not mean the treatment team or the person did something wrong.
How residual cancer is found depends on the cancer and the treatment. After surgery, a pathologist (a doctor who examines tissue under a microscope) checks the edges, or margins, of the removed tissue. A negative or clear margin means no cancer cells were found at the edge. A positive margin means cancer cells reached the edge, suggesting some cancer may have been left behind. A positive margin is a warning sign rather than proof: when more tissue is removed, no remaining cancer is sometimes found. When chemotherapy or other treatment is given before surgery, the pathologist also reports whether any cancer remains in the removed tissue. Finding none is called a pathologic complete response. Imaging such as CT, MRI or PET scans, blood tumor markers and biopsies can show remaining disease that is large enough to detect. For blood cancers such as leukemia and lymphoma, MRD tests on blood or bone marrow can find as few as one cancer cell among about a million normal cells. Newer blood tests for circulating tumor DNA (ctDNA), small pieces of DNA shed by tumor cells, can signal residual disease after treatment of some solid cancers. They are good at predicting which people are more likely to relapse, but it has not yet been shown that changing treatment based on them improves outcomes, so they are used selectively and in clinical trials.
Treatment depends on the cancer type, where the residual disease is and how much remains. Options aim either to remove what is left or to lower the chance it grows back. For cancer left at the surgical edge, a second operation to remove more tissue (re-excision) or radiation therapy to the area are common choices. For larger amounts that cannot be removed, chemotherapy, radiation, hormone therapy, targeted drugs or immunotherapy may be used to shrink or control the cancer. Additional treatment given after the main treatment, called adjuvant therapy, is often recommended when residual disease is found, to reduce the chance of the cancer returning. In some cancers the result changes the plan directly. For example, people with HER2-positive early breast cancer (cancer with high levels of the growth-promoting protein HER2) who still have invasive cancer after treatment before surgery may be offered ado-trastuzumab emtansine (Kadcyla), a targeted antibody linked to a chemotherapy drug. In B-cell acute lymphoblastic leukemia that is in remission but still MRD-positive, blinatumomab (Blincyto), an immunotherapy that directs the immune system's T cells to leukemia cells, is approved to clear remaining disease. Each added treatment brings its own side effects, so the decision weighs how likely the residual cells are to cause a relapse against the burden of more therapy. Clinical trials are an option for many people, especially where the best approach is not settled.
Learning that cancer remains after treatment can be discouraging, but it is a common situation and does not on its own mean treatment has failed or that the cancer cannot be controlled. What it means depends heavily on the cancer type and how much is left. In advanced ovarian cancer, for example, people with no visible cancer left after surgery tend to live longer than those with visible tumor remaining. A microscopic positive margin often leads to one more procedure rather than a change in outlook. When no residual disease is found, the cancer may be in complete remission, meaning no signs of cancer can be detected. Remission is encouraging, but it does not always mean cure, which is why follow-up continues. Follow-up usually involves regular visits, physical exams and, depending on the cancer, blood tests, imaging or repeat MRD testing to check whether cancer is coming back.
Ask your care team to explain your pathology report, margin status or MRD results if they are unclear, and keep scheduled follow-up appointments and tests even when you feel well. Contact your care team promptly about new or returning symptoms, such as a new lump, unexplained weight loss, persistent pain or symptoms like those you had before diagnosis, since these can be early signs that cancer is growing again.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Residual Cancer is like, what's helped you, or ask the community a question.